Connect with us

Hi, what are you looking for?

Investing

BridgeBio Pharma Shares Rise 14% on Expected Results from Heart-Disease Study

By Sabela Ojea


Shares of BridgeBio Pharma climbed 14% to $20.85 in after-hours Friday trading after the company said it would share results from the latest phase of its transthyretin amyloid cardiomyopathy heart disease study.

The commercial-stage biopharmaceutical company is set to make public findings from the phase 3 ATTRibute-CM clinical study during an investor call on Monday.

Transthyretin amyloid cardiomyopathy is a rare cause of restrictive cardiomyopathy.


Write to Sabela Ojea at [email protected]


Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Uncategorized

You will find a colossal development of the brand new discount, trading, research, as well as thousands of breakthroughs and you will inventions, and...

Uncategorized

Content Igt: Leader Del Settore Per Le Slot Machine Play Free Igt Cats Online Slot An Iconic Pokies Machine Le Slot Machine Online Sono...

Uncategorized

Blogs Instant commission casinos and you will bonuses Responsible Gambling You can even ban yourself away from several internet sites immediately by playing with...

Uncategorized

Blogs Which are the finest online casino games? Harbors out of Las vegas – Most Reputable Internet casino to own Cellular They just need...